The Medical Letter on Drugs and Therapeutics
Extended-Release Hydrocodone (Zohydro ER) for Pain
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved an extended-release oral formulation of the opioid agonist hydrocodone (Zohydro ER – Zogenix) for management of pain severe enough to require continuous, long-term therapy and for which alternative treatment options are inadequate. Zohydro ER is the first single-ingredient hydrocodone product to be marketed in the US. Hydrocodone has been available for years in combination with acetaminophen (Vicodin, and others) or ibuprofen (Vicoprofen, and others).1

PHARMACOLOGY — Hydrocodone is a semisynthetic opioid. It is metabolized primarily by CYP3A4-mediated N-demethylation to norhydrocodone and to a lesser extent by CYP2D6-mediated O-demethylation to hydromorphone. Overall hydrocodone exposure is similar after administration of Zohydro ER or comparable daily doses of immediate-release hydrocodone combination products, but ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Extended-Release Hydrocodone (Zohydro ER) for Pain
Article code: 1444b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian